Trial of Moxifloxacin-containing Triple Therapy after Initial and Second-line Treatment Failures for Helicobacter pylori Infection.
- Author:
Jae Hee CHEON
1
;
Nayoung KIM
;
Dong Ho LEE
;
Jin Wook KIM
;
Jin Hyeok HWANG
;
Young Soo PARK
;
Jung Mogg KIM
;
Seong O SUH
;
Hyun Chae JUNG
;
In Sung SONG
Author Information
1. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; English Abstract
- Keywords:
Helicobacter pylori;
Second-line therapy;
Rescue therapy;
Moxifloxacin
- MeSH:
Adult;
Aged;
Antacids/administration & dosage;
Anti-Bacterial Agents/administration & dosage;
Aza Compounds/*administration & dosage;
Bismuth/administration & dosage;
Drug Therapy, Combination;
Female;
Helicobacter Infections/*drug therapy;
*Helicobacter pylori;
Humans;
Male;
Middle Aged;
Proton Pumps/antagonists & inhibitors;
Quinolines/*administration & dosage
- From:The Korean Journal of Gastroenterology
2005;45(2):111-117
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Proton-pump inhibitor (PPI)-based triple therapy for Helicobacter pylori eradication is widely used with considerable failure rate. Bismuth-based, second-line therapy is also associated with failures in more than 20% of cases in Korea. Our aim was to evaluate the efficacy and tolerability of third-line therapy containing moxifloxacin as a rescue in Korea. METHODS: The subjects consisted of 201 patients infected with H. pylori, who were treated with PPI-based therapy, 42 patients treated with bismuth-based after failure of initial PPI triple therapy, and 10 patients treated with moxifloxacin-containing triple therapy after failure of successive initial and second-line therapy. Eradication rate, compliance and side effect rates were compared. RESULTS: The eradication rates of initial, second-line, and third-line therapy were as follows: 67.2%/83.3%, 54.8%/76.7%, 80.0%/88.9% by intention-to-treat and per protocol analysis, respectively. The compliance of patients for each treatment was 98.2%, 90.9%, 100%, respectively. The side effect rate was significantly higher in the bismuth triple therapy than in the PPI- or moxifloxacin-containing triple therapy (p<0.05). CONCLUSIONS: Moxifloxacin-containing triple therapy shows high eradication rate with fewer side effects and good compliance. Thus, this regimen could be used as a rescue therapy.
